GenVec, Inc.
GNVC
NASDAQ7.19
USD
-0.02
- -
CIK
0000934473
Return %
Stock
S&P500
1Y
- -
26.57
3Y
- -
76.60
5Y
- -
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- IPO Date
- Dec 12, 2000
- CIK
- 0000934473
- Similar Companies
- Business
- GenVec, Inc. (GNVC) develops therapeutics and vaccines using its proprietary AdenoVerse gene delivery platform based on adenoviral vectors; core products include CGF166 in Phase I/II trials for hearing loss and balance disorders, GV2311 vaccine candidates for respiratory syncytial virus, GV2207 for herpes simplex virus, and preclinical programs for malaria, dengue fever, and foot-and-mouth disease in livestock; the company licenses its vectors, production cell lines, and manufacturing services to biopharmaceutical partners targeting infectious diseases, oncology, and gene therapy applications. Founded in 1992 and headquartered in Gaithersburg, Maryland, GenVec operates primarily in the United States with global collaborations including Novartis for CGF166 development, the U.S. Naval Medical Research Center for malaria and dengue vaccines, and prior agreements with TheraBiologics for cancer therapeutics and Merial for animal health. In 2017, Intrexon Corporation acquired GenVec in an all-stock transaction valuing it at approximately $14.9 million to integrate and expand the AdenoVerse platform for next-generation high-payload adenoviral delivery exceeding 30kb capacity; the company is now listed as a subsidiary in an acquired and closed status with no major public updates on operations, funding, or new launches since the acquisition.